Bumetanide
Bumetanide, sold as Bumex, is a loop diuretic, a medicine taken by mouth that acts on the kidney. The US label read, for Bumex tablets, lists swelling from fluid build-up in people with congestive heart failure, liver disease and kidney disease, including the nephrotic syndrome. The label carries a boxed warning that the medicine is a potent diuretic and, in excessive amounts, can lead to a profound loss of water and salts from the body.
Also called Bumex
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 1808; UNII 0Y2S3XUQ5H. MeSH descriptor D002034 is Bumetanide. Class: Loop Diuretic (FDA established pharmacologic class, RxClass). The label read is the Validus Pharmaceuticals LLC label for Bumex tablets, application NDA018225, effective 2025-09-08 in openFDA. Bumetanide injection labels (for example ANDA applications) and generic labels were not read. The label says safety and effectiveness in patients under 18 have not been established; that statement was not recorded as a claim. This page records label indications, the title and first sentence of the boxed warning, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says bumetanide inhibits sodium reabsorption in the ascending limb of the loop of Henle.
Claims and evidence
Context Patients with edema from congestive heart failure, liver disease or kidney disease, as described in the US label of Bumex tablets
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label: people with edema associated with congestive heart failure, hepatic disease or renal disease, including the nephrotic syndrome. The passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with edema associated with congestive heart failure, hepatic disease or renal disease, including the nephrotic syndrome
- Excluded
- None stated
The US label of Bumex (bumetanide tablets, Validus Pharmaceuticals LLC, application NDA018225; the version dated 2025-09-08 in openFDA) lists the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. It describes bumetanide as a loop diuretic. The label carries a boxed warning that the medicine is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion.
Applies to Recipient not specified Patients with edema from congestive heart failure, liver disease or kidney disease, as described in the US label of Bumex tablets
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for and the boxed warning's first sentence. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The boxed warning goes on to say what prescribers must do; that instruction is not repeated here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].indications_and_usage[0], INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2025-09-08
- Source state
- Current
- Version fingerprint
6097bcd5b6638cd4d11c8aea78439d1b9d73e8e69002fdc2f0399cadd90f1455- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].clinical_pharmacology[0], first sentence
- How it applies
- Label passage quoted in the research quote table (LB-05).
- Retrieved
- Source effective date
- 2025-09-08
- Source state
- Current
- Version fingerprint
6097bcd5b6638cd4d11c8aea78439d1b9d73e8e69002fdc2f0399cadd90f1455- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first sentence
- How it applies
- Label passage quoted in the research quote table (LB-06).
- Retrieved
- Source effective date
- 2025-09-08
- Source state
- Current
- Version fingerprint
6097bcd5b6638cd4d11c8aea78439d1b9d73e8e69002fdc2f0399cadd90f1455- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250908.
- Retrieved
- Source effective date
- 2025-09-08
- Source state
- Current
- Version fingerprint
6097bcd5b6638cd4d11c8aea78439d1b9d73e8e69002fdc2f0399cadd90f1455- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists edema associated with congestive heart failure as an indication: Heart failure
Applies to Recipient not specified Patients with edema from congestive heart failure, liver disease or kidney disease, as described in the US label of Bumex tablets
The US label of Bumex (bumetanide tablets, Validus Pharmaceuticals LLC, application NDA018225; the version dated 2025-09-08 in openFDA) lists the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. It describes bumetanide as a loop diuretic. The label carries a boxed warning that the medicine is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion.Limitations. This claim records what one US label says the medicine is indicated for and the boxed warning's first sentence. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The boxed warning goes on to say what prescribers must do; that instruction is not repeated here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:bumetanide- Content hash
d4dacfb3343cd13e17db6e2964c75fdd1284a8c7cfd111edf870e43c73e71515